Skip to main content
  • Investors
  • Mediaopen in a new window
  • Contact Usopen in a new window
  • |
Ironwood Logoopen in a new window
  • Company
  • Science & Medicine
  • Patients
  • Responsibility
  • Careers
  • IR Home
  • Why Invest
  • Events & Presentations
  • Corporate Governance
    • Governance Documents
    • Executive Management
    • Board of Directors
    • Committee Composition
    • Contact the Board
  • Financials
    • Quarterly Results
    • Annual Reports
    • SEC Filings
  • Investor FAQs
  • Press Releases
  • Investor Contacts
    • Investor Emails Alerts
    • RSS Feeds
  • IR Home
  • Why Invest
  • Events & Presentations
  • Corporate Governance
    • Governance Documents
    • Executive Management
    • Board of Directors
    • Committee Composition
    • Contact the Board
  • Financials
    • Quarterly Results
    • Annual Reports
    • SEC Filings
  • Investor FAQs
  • Press Releases
  • Investor Contacts
    • Investor Emails Alerts
    • RSS Feeds
Close
Close
  • Investors
  • Company
  • Product
  • Research & Development
  • Patients
  • Partnerships
  • Careers
Close

Press Releases

Normal
Press Release RSS Feed (opens in new window)
Press release year list 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008
December 1, 2021
Ironwood Pharmaceuticals Appoints Sravan K. Emany as Chief Financial Officer
November 4, 2021
Ironwood Pharmaceuticals Reports Third Quarter 2021 Results and Provides Corporate Development Update
November 4, 2021
Ironwood Pharmaceuticals Expands Pipeline by Signing an Option Agreement to Acquire an Exclusive License with COUR Pharmaceuticals to Develop and Commercialize CNP-104 for the Treatment of Primary Biliary Cholangitis (PBC) in the U.S.
October 25, 2021
More than 90% of Surveyed IBS-C Patients Who Had an ER Visit or Hospitalization in the Past Year Identified Abdominal Pain as a Symptom That Led to the Visit, According to Data Announced by Ironwood Pharmaceuticals at ACG 2021
October 21, 2021
Ironwood Pharmaceuticals to Host Third Quarter 2021 Investor Update Call
September 2, 2021
Ironwood Pharmaceuticals to Participate in Upcoming September Investor Conferences
August 26, 2021
Ironwood Pharmaceuticals Announces FDA Approval of Revised LINZESS® (linaclotide) Label
August 5, 2021
Ironwood Pharmaceuticals Reports Strong Second-Quarter 2021 Results, Raises Full-Year Guidance
August 3, 2021
Ironwood Pharmaceuticals Appoints John Minardo as Chief Legal Officer
July 22, 2021
Ironwood Pharmaceuticals to Host Second Quarter 2021 Investor Update Call
June 16, 2021
Ironwood Pharmaceuticals Announces That The American Journal of Gastroenterology Publishes Full Results from Positive LINZESS® (linaclotide) Phase IIIb Trial in Adults with Irritable Bowel Syndrome with Constipation (IBS-C)
June 7, 2021
Ironwood Pharmaceuticals Announces Leadership Updates
May 26, 2021
Ironwood Pharmaceuticals Announces Agreement with Teva Involving LINZESS® (linaclotide) 72 mcg Dosage Strength
May 24, 2021
More Than a Third of Surveyed IBS-C Patients Reported That Their Symptoms Worsened During COVID-19 According to New Survey Findings Presented by Ironwood Pharmaceuticals at Digestive Disease Week® (DDW)
May 17, 2021
Ironwood Pharmaceuticals to Present New Linaclotide Data and Unveil Findings From GI Disease Surveys at Digestive Disease Week® 2021
May 6, 2021
Ironwood Pharmaceuticals Announces New $150 Million Share Repurchase Program
May 6, 2021
Ironwood Pharmaceuticals Reports First Quarter 2021 Results
April 22, 2021
Ironwood Pharmaceuticals to Host First Quarter 2021 Investor Update Call
February 19, 2021
Ironwood Pharmaceuticals to Present at Upcoming Investor Conferences
February 17, 2021
Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Results, Exceeding or Meeting Full Year 2020 Financial Guidance; Provides Full Year 2021 Financial Guidance
February 8, 2021
Ironwood Pharmaceuticals Announces CEO Transition
February 3, 2021
Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2020 Investor Update Call
January 5, 2021
Ironwood Pharmaceuticals to Present at the 39th Annual J.P. Morgan Healthcare Conference

Investor Alerts

To opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. After submitting your request, you will receive an activation email to the requested email address. You must click the activation link in order to complete your subscription. You can sign up for additional alert options at any time.

At Ironwood Pharmaceuticals, Inc., we strive to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance.

By providing your email address below, you are providing consent to Ironwood Pharmaceuticals, Inc. to send you the requested Investor Email Alert updates.

* Required

*
*





Email Alert Sign Up Confirmation

Ironwood Logoopen in a new window
  • Investors
  • Media
  • Contact us
Follow us on Linkedin Follow us on Twitter

COMPANY

  • Company Overview
  • Leadership
  • Open Payments & Transparecy

PRODUCT

  • Linzees

RESEARCH & DEVELOPMENT

  • Pipeline
  • Medical Affairs

PARTNERSHIPS

  • Overview
  • Grants

PATIENTS

  • Overview

RESPONSBILITY

  • Overview
  • Community Giving
  • Equity,Diversity & Inclusion
  • Sustainability
  • Safety & Compliance
  • Patients & Research

CAREERS

  • Working at Ironwood
  • Open Positions
  • Internships, Co-ops & Fellowships

INVESTORS

  • Home
  • Why Invest
  • Events & Presentations
  • Corporate Governance
  • Finanical Information
  • Investor FAQ
  • Press Releases
  • Investor Contacts
  • Copyright © Ironwood. All rights reserved Powered By Q4 Inc. 5.77.0.2 (opens in new window)
  • Privacy Policy
  • California Privacy Policy
  • Site Map
  • Terms of Use